Hong Li

7652049, Jan 26, 2010

Jul 1, 2005

11/173295

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

Merck & Co., Inc. - Rahway NJ

C07D 263/20
A61K 31/4015

514376, 514340, 514361, 514386, 5462714, 548125, 548224, 5483661

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:.

7910592, Mar 22, 2011

Dec 29, 2006

12/087185

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Christopher F. Thompson - Clark NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/497
A61K 31/427
A61K 31/422
A61K 31/506
C07D 239/02
C07D 241/02
C07D 401/02
C07D 277/02
C07D 263/02

51425505, 514256, 514365, 514376, 544242, 544336, 5462714, 548202, 548230

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

7915271, Mar 29, 2011

Dec 29, 2006

12/087290

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/4166
A61K 31/44
A61K 31/506
C07D 239/34
C07D 413/10
C07D 263/06

514274, 514326, 514376, 544315, 546209, 5462714, 548229

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

8440702, May 14, 2013

Mar 28, 2011

13/073190

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/4166
A61K 31/44
C07D 413/10

514340, 5462714

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

20080119476, May 22, 2008

Jul 1, 2005

11/631821

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Palins NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

A61K 31/422
A61K 31/40
A61K 31/4166
A61K 31/427
A61K 31/4439
A61K 31/501
A61P 9/10
C07D 233/32
C07D 263/20
C07D 417/10
C07D 417/04
C07D 413/10
C07D 413/04
C07D 401/04
C07D 285/10
C07D 233/44
C07D 207/24
A61K 31/506
A61K 31/497
A61K 31/433
A61K 31/4168
A61K 31/421

51425205, 51425505, 514256, 514340, 514341, 514362, 514372, 514376, 514392, 514424, 514426, 544238, 544333, 544405, 5462714, 5462741, 548134, 548200, 548229, 5483235, 5483315, 548551

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

20100099716, Apr 22, 2010

Nov 25, 2009

12/625783

Amjad ALI - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

A61K 31/421
C07D 263/04
C07D 413/04
A61K 31/4439
A61P 9/10

514340, 548229, 5462714, 514376

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

20130072492, Mar 21, 2013

May 24, 2011

13/699046

Subharekha Raghavan - Teaneck NJ, US
John E. Stelmach - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Alan Whitehead - Scotch Plains NJ, US
Sherman T. Waddell - Westfield NJ, US
Yi-Heng Chen - Whippany NJ, US
Shouwu Miao - Edison NJ, US
Olga A. Ornoski - Teaneck NJ, US
Joie Garfunkle - Metuchen NJ, US
Xibin Liao - Edison NJ, US
Jiang Chang - Westfield NJ, US
Xiaoqing Han - Edison NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan A. Groeper - Metuchen NJ, US
Linda L. Brockunier - Orange NJ, US
Keith Rosauer - New Hampton IA, US
Emma R. Parmee - Doylestown PA, US

C07D 487/04
C07D 495/04
A61K 31/5025
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 3/00
A61P 3/06
A61P 7/10
A61K 31/519

514248, 544280, 5142651, 544236, 51425505, 544281, 5142591

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

20180051043, Feb 22, 2018

Mar 25, 2016

15/560896

- Rahway NJ, US
Sherman T. Waddell - Westfield NJ, US
John A. McCauley - Maple Glen PA, US
Thomas H. Graham - Quincy MA, US
Hong Li - Edison NJ, US
Izzat Raheem - Doylestown PA, US
Jay A. Grobler - North Wales PA, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07F 9/6561
A61K 31/683
A61K 31/675

The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Phosphate Substituted Quinolizine Derivative, and methods of using the Phosphate Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.